DB16318InvestigationalProtein Based Therapies
Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis).
- Mechanism
- Curator reviewed
Pharmacologically active on Interleukin-13 and Interleukin-4
- Also known as
- Bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13) · Hutbti3_2_1
- Code names
- SAR-156597
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Romilkimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account